India, March 27 -- The Government of India has issued a release:
S. No.
Name of the Company
Product
District
Project Location (State)
1.
Aurobindo Pharma Limited Through Lyfius Pharma Pvt Ltd.
Penicillin G
East Godavari
Andhra Pradesh
2.
Karnataka Antibiotics and Pharmaceuticals Limited
7 ACA
Ujjain
Madhya Pradesh
3.
Kinvan Private Limited
Clavulanic Acid
Solan
Himachal Pradesh
4.
Orchid Bio-Pharma Limited
7 ACA
Kathua
Jammu & Kashmir
5.
Macleods Pharmaceutical Limited
Rifampicin
Bharuch
Gujarat
6.
Natural Biogenex Private Limited
Betamethasone
Tumkur
Karnataka
7.
Natural Biogenex Private Limited
Dexamethasone
Tumkur
Karnataka
8.
Natural Biogenex Private Limited
Prednisolone
Tumkur
Karnataka
9.
Symbiotec Pharmalab Private Limited
Prednisolone
Dhar
Madhya Pradesh
10.
Emmennar Pharma Pvt Ltd.
1,1 Cyclohexane Diacetic Acid (CDA)
Sangareddy
Telangana
11.
Granules India Limited
Dicyandiamide (DCDA)
Visakhapatnam & Kakinada (2 locations)
Andhra Pradesh
12.
Hindys Lab Pvt Ltd.
1,1 Cyclohexane Diacetic Acid (CDA)
Nalgonda
Telangana
13.
Meghmani LLP
Para Amino Phenol
Bharuch
Gujarat
14.
Sadhana Nitro Chem Ltd.
Para Amino Phenol
Raigad
Maharashtra
15.
Alta Laboratories Limited
Aspirin
Raigad
Maharashtra
16.
Amoli Organics Private Limited
Diclofenac Sodium
Valsad
Gujarat
17.
Anasia Lab Private Limited
Losartan
Nalgonda
Telangana
18.
Anasia Lab Private Limited
Olmesartan
Nalgonda
Telangana
19.
Andhra Organics Limited
Olmesartan
Srikakulam
Andhra Pradesh
20.
Andhra Organics Limited
Sulfadiazine
Srikakulam
Andhra Pradesh
21.
Andhra Organics Limited
Telmisartan
Srikakulam
Andhra Pradesh
22.
Aviran Pharmachem Private Limited
Artesunate
Mehsana
Gujarat
23.
Centrient Pharmaceuticals India Private Limited
Atorvastatin
Nawanshahr
Punjab
24.
Dasami Lab Pvt Ltd.
Carbamazepine
Nalgonda
Telangana
25.
Dasami Lab Pvt Ltd.
Oxcarbazepine
Nalgonda
Telangana
26.
Global Pharma Healthcare Private Limited
Ofloxacin
Tiruvannamalai
Tamil Nadu
27.
Globela Industries Pvt Ltd
Norfloxacin
Bharuch
Gujarat
28.
Globela Industries Pvt Ltd
Ofloxacin
Bharuch
Gujarat
29.
Hazelo Lab Pvt Ltd.
Vitamin B6
Yadadri
Telangana
30.
Hetero Drugs Limited
Carbidopa
Visakhapatnam
Andhra Pradesh
31.
Hetero Drugs Limited
Levodopa
Visakhapatnam
Andhra Pradesh
32.
Hetero Drugs Limited
Levofloxacin
Sangareddy
Telangana
33.
Hetero Drugs Limited
Oxcarbazepine
Sangareddy
Telangana
34.
Hindys Lab Pvt Ltd.
Acyclovir
Nalgonda
Telangana
35.
Honour Lab Limited
Levetiracetam
Sangareddy
Telangana
36.
Honour Lab Limited
Lopinavir
Visakhapatnam
Andhra Pradesh
37.
Honour Lab Limited
Valsartan
Sangareddy
Telangana
38.
Honour Lab Limited
Vitamin B6
Visakhapatnam
Andhra Pradesh
39.
K P Manish Global Ingredients Pvt Ltd.
Artesunate
Cuddalore
Tamil Nadu
40.
Kreative Actives Private Limited
Diclofenac Sodium
Visakhapatnam
Andhra Pradesh
41.
MSN Life Sciences Pvt Ltd.
Levofloxacin
Medak
Telangana
42.
RMC Performance Chemicals Private Limited
Aspirin
Jalgaon
Maharashtra
43.
Sudarshan Pharma Industries Ltd.
Vitamin B1 (Chemical Synthesis Route)
Raigad
Maharashtra
44.
Sudarshan Pharma Industries Ltd.
Vitamin B6
Raigad
Maharashtra
45.
Vital Laboratories Private Limited
Levofloxacin
Valsad
Gujarat
46.
Vital Laboratories Private Limited
Ofloxacin
Valsad
Gujarat
47.
Sustainable Environment Developers Limited
Erythromycin Thiocynate (TIOC)
SAS Nagar
Punjab
48.
Orgo Pharma and Fuels LLP
2-Methyl-5Nitro-Imidazole (2-MNI)
Yamuna Nagar
Haryana
The Government has launched the PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs) to promote the establishment of new pharmaceutical industrial units. The PLI Scheme for Bulk Drugs has a budgetary outlay of Rs.6,940 crore, and it aims to improve self-reliance and reduce import dependence in critical KSMs, DIs and APIs. As of December 2025, 48 greenfield projects have been approved under the scheme with committed investment of Rs.4,329.95 crore, against which actual investment of Rs.4,814.1 crore has been made. 38 projects have been commissioned, resulting in establishment of domestic manufacturing capacity of approximately 56,800MT per annum. Details of projects approved under PLI Scheme for Bulk Drugs, State-wise and district-wise are placed at Annexure.
The Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme has been launched by the Government with an outlay of Rs.5,000 crore to transform India's Pharma MedTech sector including Madhya Pradesh and Dadra and Nagar Haveli, from cost-based to innovation-based growth by strengthening research and to promote industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this, seven Centres of Excellence (CoEs) have been set up, with total budgetary support to the tune of Rs.700 crore, to create research infrastructure and promote R&D in identified areas. The CoEs have so far approved 104 research projects under the scheme and have filed two patents. The scheme also includes an outlay of Rs.4,250 crore for support to industry and startups, including in collaboration with academia, for undertaking research and innovation projects in priority areas.
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana was launched by the Government of India to make quality generic medicines available at affordable prices for all citizens. Under this scheme, special outlets called Jan Aushadhi Kendras are opened across the country which provide medicines that are about 50% to 80% cheaper than branded medicines, helping reduce healthcare expenses for patients. Under the scheme, 634 JAKs in Madhya Pradesh and 41 JAKs in the Union Territory of Dadra and Nagar Haveli and Daman & Diu have been opened which aim to increase the availability of affordable medicines in Madhya Pradesh and Union Territory of Dadra and Nagar Haveli and Daman & Diu. Further, to increase availability of medicines, Pharmaceutical & Medical Devices Bureau of India (PMBI), which is the implementing agency of the PMBJP scheme, utilises an end-to-end information-technology-enabled supply chain system through which availability of medicines are monitored in these JAKs. The JAKs are incentivised to maintain the stocks of 200 high demand products under the scheme. In addition, 400 fast-moving products are monitored regularly by PMBI with periodic forecasting aided by digital tools.
Annexure
Details of approved projects under the PLI Scheme for Bulk Drugs, State-wise and district-wise:
This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.
Disclaimer: Curated by HT Syndication.
